Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial

Paul A. Richardson(Johns Hopkins University), Trần Việt Hà(University of North Carolina at Chapel Hill), Meredith E. Clement(Louisiana State University Health Sciences Center New Orleans), Matthew A. Spinelli(University of California, San Francisco), Adeola Adeyeye(National Institutes of Health), Myron S. Cohen(University of North Carolina at Chapel Hill), Beatriz Grinsztejn(Fundação Oswaldo Cruz), Estelle Piwowar‐Manning(Johns Hopkins University), Raphael J. Landovitz(APLA Health), Marybeth McCauley(Family Health International 360), James F. Rooney(Gilead Sciences (United States)), Esper G. Kallás(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Craig W. Hendrix(Unknown), Peter L. Anderson(University of Colorado Denver), HPTN Study Team, Omar Sued(Fundación Huésped), Jonathan Lucas(Family Health International 360), Deborah Donnell(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Hyman Scott(UCLA Medical Center), Manya Magnus(Milken Institute), Carlos del Rı́o(Emory University), Philip A. Sullivan(Johns Hopkins University), Susan H. Eshleman(Johns Hopkins University), Ryan Kofron(APLA Health), Mark A. Marzinke(Family Health International 360), Brett Hanscom(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Alex R. Rinehart, Richard Berman(The Christie NHS Foundation Trust), Joe Eron(University of North Carolina at Chapel Hill), Sheldon D. Fields(Pennsylvania State University), Jorge Sánchez(Universitat Politècnica de València)
UNC Libraries
January 25, 2025
Cited by 1


Related Papers